Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 4—April 2015

Enterovirus A71 Subgenotype B5, France, 2013

On This Page
Article Metrics
citations of this article
EID Journal Metrics on Scopus

Cite This Article

To the Editor: We report the detection of human enterovirus A71 (EV-A71) subgenotype B5 in France, 6 years after it was first detected in Europe. EV-A71 belongs to the Enterovirus A species (genus Enterovirus, family Picornaviridae) and is a major cause of hand, foot and mouth disease (HFMD), sometimes associated with severe neurologic complications (1). EV-A71 strains are classified in 6 genotypes, A–F, (2) but most of the circulating strains belong to genotypes B and C and to 11 subgenotypes (B0−B5, C1−C5) (1). Genotypes B and C have been reported in HFMD epidemics in the Asia-Pacific region; different subgenotypes cause nationwide epidemics that usually occur every 2−3 years (1). During 1963−1986 in Europe, Australia, and the United States, enterovirus infections were caused by viruses from subgenotypes B0, B1, and B2, but since 2000, infections with C1 and C2 viruses have begun to predominate (3,4). The other subgenotypes have been reported rarely in Europe; the C4b and C4a strains were identified in France, Germany, Austria, and Denmark in 2004 and 2012, respectively (46), and the B5 subgenotype was reported in Denmark in 2007 (7).

In November 2013, a 3-week-old boy was admitted to the emergency unit of a hospital in Compiègne, France, with a 48-hour history of fever and irritability. He was born at term after an uneventful pregnancy and delivery. On admission, he had normal vital signs. He had had contact with a cousin with oral ulcerations, but no information was available about the source of the cousin’s infection.

Laboratory testing revealed moderate cytolytic hepatitis. Complete blood count results were within reference values. Cerebrospinal fluid showed pleiocytosis (38 leukocytes, 81% polymorphonuclear cells) with protein and glucose levels with reference ranges. Bacterial cultures of blood and cerebrospinal fluid were negative. Enterovirus genome was detected in serum samples and cerebrospinal fluid by reverse transcription PCR. The infant made a steady recovery and was discharged 10 days after admission, with no apparent adverse outcome. Final diagnosis was neonatal enterovirus infection with meningitis.

Genotyping was performed on the serum specimen by using seminested reverse transcription PCR amplification and sequencing of the viral protein 1 gene. Phylogenetic investigation with sequences of reference strains representing all subgenotypes indicated that the isolate from the patient, designated PAR024102_FRA13, belonged to the EV-A71 B5 subgenotype. We investigated the putative origin of the strain by comparing 248 nonredundant complete 1D sequences of EV-A71 B5 strains following a Bayesian phylogenetic approach. PAR024103_FRA13 shared a most recent common ancestor (posterior probability = 1) with virus strains sampled in China in 2009 and in Taiwan during the 2011–2012 outbreak, (8) but was only distantly related to them (data not shown).


Thumbnail of Phylogeny of enterovirus A71 (EV-A71) subgenogroups B4 and B5 inferred with 274 partial 1D gene sequences, France. Black diamond indicates strain PAR024103_FRA13 from this study. The phylogenetic relationships were inferred following a Bayesian method by using a relaxed molecular clock model with an uncorrelated exponential distribution of evolution rates estimated with a general time reversible substitution model and a Bayesian skyline plot as a population model (BEAST version 1.7.

Figure. Phylogeny of enterovirus A71 (EV-A71) subgenogroups B4 and B5 inferred with 274 partial 1D gene sequences, France. Black diamond indicates strain PAR024103_FRA13 from this study. The phylogenetic relationships were inferred following...

Further analyses with 274 partial 1D gene sequences from GenBank (on March 19, 2014) indicated close genetic relationships (posterior probability = 1) with strains isolated in Thailand in 2012 (9) (Figure). The complete genome of PAR024103_FRA13 was determined by nucleotide sequencing of 4 overlapping segments obtained by gene amplification (GenBank accession no. LK985324). Sequence comparisons were performed with 13 available EV-A71 B5 complete genomes; the virus strain isolated in France exhibited 92%−99.5% nt similarity (98.9%−99.4% aa similarity) throughout the genome.

The EV-A71 B5 subgenotype was first detected in 1999 in Malaysia and spread to several other countries in Asia during the 2000s. Outbreaks causing severe illness and deaths were reported in Japan (2003), Brunei (2006), and Taiwan (2008 and 2012) (1,8). The first detection of subgenotype B5 in Europe was associated with a recrudescence of EV-A71 infections associated with meningitis and HFMD in Denmark in 2007 (7). The overall phylogenetic data are consistent with an introduction of EV-A71 B5 in France by importation of a strain from Asia, possibly from Thailand. Transmission of EV-A71 strains has been shown to occur in Europe as discrete and temporally defined virus introductions, occasionally followed by sustained dissemination (C. Hassel, unpub. data).

The emergence of the Asiatic lineage EV-A71 C4a in Denmark in 2012 is a recent event (6). The reemergence of EV-A71 subgenotype B5 in 2008 in Taiwan resulted in the largest outbreak of EV-A71 infection in the past 11 years (8). To our knowledge, the B5 subgenotype has not previously been detected in Europe. Global herd immunity produced by circulation of the C2 genotype may protect the European population from the spread of other subgenotypes (3). However, given that most countries in Europe do not perform specific surveillance for HFMD and most enterovirus infections are asymptomatic, this particular subgenotype could be circulating more widely without detection.

Enterovirus infections in neonates and infants are a frequent cause of hospitalization, which may contribute to EV-A71 detection (5). However, the development of a national syndromic surveillance targeting HFMD would enable early detection of HFMD outbreaks and any new EV-A71 subgenotype. Attention should also be paid to the potential risks of epidemic spread of EV-A71 outside Asia posed by international travelers.



We are grateful to Nathalie Rodde and Gwendoline Jugie for excellent technical assistance in enterovirus genotyping and complete genome sequencing. We thank Jeffrey Watts for revising the English manuscript.

The Centre National de Référence des Enterovirus-Parechovirus is supported by an annual grant from the French national public health network (Institut de Veille Sanitaire).


Audrey MirandComments to Author , Lucie Molet, Chervin Hassel, Hélène Peigue-Lafeuille, Flore Rozenberg, Jean-Luc Bailly, and Cécile Henquell
Author affiliations: Clermont Université, Clermont-Ferrand, France (A. Mirand, C. Hassel, H. Peigue-Lafeuille, J.-L. Bailly, C. Henquell); Centre National de Référence des Entérovirus-Parechovirus, Clermont-Ferrand (A. Mirand, H. Peigue-Lafeuille, J.-L. Bailly, C. Henquell); Hôpital Cochin, Paris, France (L. Molet, F. Rozenberg); Université Paris Descartes, Paris (L. Molet, F. Rozenberg)



  1. Solomon  T, Lewthwaite  P, Perera  D, Cardosa  MJ, McMinn  P, Ooi  MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10:77890. DOIPubMedGoogle Scholar
  2. Bessaud  M, Razadindratsimandresy  R, Nougairède  A, Joffret  ML, Deshpande  JM, Dubot-Pérès  A, Molecular comparison and evolutionary analyses of VP1 nucleotide sequences of new African human enterovirus 71 isolates reveal a wide genetic diversity. PLoS ONE. 2014;9:e90624. DOIPubMedGoogle Scholar
  3. van der Sanden  S. van der Avoort, Lemey P, Uslu G, Koopmans M. Evolutionary trajectory of the VP1 gene of human enterovirus 71 genogroup B and C viruses. J Gen Virol. 2010;91:194958. DOIPubMedGoogle Scholar
  4. Mirand  A, Schuffenecker  I, Henquell  C, Billaud  G, Jugie  G, Falcon  D, Phylogenetic evidence of a recent spread of two populations of human enterovirus 71 in European countries. J Gen Virol. 2010;91:226377. DOIPubMedGoogle Scholar
  5. Schuffenecker  I, Henquell  C, Mirand  A, Coste-Burel  M, Marque-Juillet  S, Desbois  D, New introductions of enterovirus 71 subgenogroup C4, France, 2012. Emerg Infect Dis. 2014;20:1343–6.
  6. Fischer  TK, Nielsen  AY, Sydenham  TV, Andersen  PH, Andersen  B, Midgley  SE. Emergence of enterovirus 71 C4a in Denmark, 2009 to 2013. Euro Surveill. 2014;19;20911.PubMedGoogle Scholar
  7. Badran  SA, Midgley  S, Andersen  P, Böttinger  B. Clinical and virological features of enterovirus 71 infections in Denmark, 2005 to 2008. Scand J Infect Dis. 2011;43:6428. DOIPubMedGoogle Scholar
  8. Wu  WH, Kuo  TC, Lin  YT, Huang  SW, Liu  HF, Wang J, et al. Molecular epidemiology of enterovirus 71 infection in the central region of Taiwan from 2002 to 2012. PLoS ONE. 2013;8:e83711. DOIPubMedGoogle Scholar
  9. Linsuwanon  P, Puenpa  J, Huang  SW, Wang  YF, Mauleekoonphairoj  J, Wang  JR, Epidemiology and seroepidemiology of human enterovirus 71 among Thai populations. J Biomed Sci. 2014;21:16. DOIPubMedGoogle Scholar




Cite This Article

DOI: 10.3201/eid2104.141093

Related Links


Table of Contents – Volume 21, Number 4—April 2015

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.



Please use the form below to submit correspondence to the authors or contact them at the following address:

Audrey Mirand, CHU Clermont-Ferrand, Laboratoire de Virologie, Centre National de Référence des Entérovirus-Parechovirus–Laboratoire Associé, Clermont-Ferrand, France

Send To

10000 character(s) remaining.


Page created: March 17, 2015
Page updated: March 17, 2015
Page reviewed: March 17, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.